New results with Cefaly external trigeminal nerve stimulation device for migraine published in BMC Neurology- STX-Med
A new clinical trial reveals that Cefaly, from STX-Med, the first FDA-approved external trigeminal nerve stimulation device for the prevention of frequent episodic migraines, has been used successfully on migraine patients who do not respond to usual oral migraine medication (refractory migraine). The results, published in BMC Neurology, an international peer-reviewed publication, showed that the Cefaly treatment reduced significantly the headache days and the acute anti-migraine medication intake in migraine patients that didn't previously respond to usual preventive oral migraine medications. Two out of three patients (66%) said they were satisfied by the treatment.
The study results confirm the high efficacy of Cefaly, even when other treatments didn't work. The constant accumulation of clinical data about the Cefaly shows clearly that Cefaly, offers the best safety efficacy ratio and thus is becoming the first line treatment for patients having frequently migraine attacks.
See: "Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study." Michail Vikelis et al. MC Neurology BMC series 2017 Published: 18 May 2017 DOI: 10.1186/s12883-017-0869-3
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins